CorMedix is experiencing a dramatic commercial inflection, with revenue surging from under $1M in early 2024 to over $127M in Q1 2026, demonstrating powerful operating leverage as operating income scaled from a $16.7M loss to a $63.7M profit. The company has t...
Price trend, volume and key moving averages
Trailing total returns as of 9/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | $0.29+21.8% vs $0.24 | $102M+6.1% vs $96M |
Q2 2026 May 14, 2026 | $0.43+22.9% vs $0.35 | $127M+21.4% vs $105M |
Q2 2026 Mar 5, 2026 | $0.18-79.1% vs $0.86 | $129M+1.3% vs $127M |
Q4 2025 Nov 12, 2025 | $0.57+18.8% vs $0.48 | $104M+21.2% vs $86M |
The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8 – 10, 2026.
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Benchmark CRMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CorMedix Inc. (CRMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.77 | $609.57M | 3.81 | 617.03% | 52.31% | 66.56% | — | |
| $66.84 | $2.21B | -6.87 | -43.89% | -287.84% | -37.99% | — | |
| $111.45 | $13.22B | 43.54 | 37.55% | 24.86% | 180.63% | — | |
| $298.87 | $8.33B | -22.17 | -100% | — | -34.15% | — | |
| $26.40 | $4.52B | 11.53 | 11.87% | 33.42% | 32.39% | — | |
| $42.78 | $2.48B | -62.91 | 8.63% | -13.23% | -10.42% | — |
CorMedix Inc. (CRMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CorMedix Inc. (CRMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 7, 2026·SEC
Jul 2, 2026·SEC
Get notified when CRMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CorMedix Inc. (CRMD) stock FAQ — growth, dividends, profitability & financials explained
CorMedix Inc. (CRMD) reported $462.2M in revenue for fiscal year 2025.
CorMedix Inc. (CRMD) grew revenue by 617.0% over the past year. This is strong growth.
Yes, CorMedix Inc. (CRMD) is profitable, generating $187.2M in net income for fiscal year 2025 (52.3% net margin).
CorMedix Inc. (CRMD) has a return on equity (ROE) of 66.6%. This is excellent, indicating efficient use of shareholder capital.
CorMedix Inc. (CRMD) generated $251.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
